An ILD Mini Symposium you won't want to miss! 👉Towards Implementation: New Biomarkers in ILD ⏰ May 19, 9:15-11:15AM 📍Marriott Marquis, Grand Ballroom 8-9 (Lobby Level, North Tower) Moderators: Chad Newton, Toby Maher, & Manuela Funke-Chambour #ATS2024 American Thoracic Society (ATS)

Congratulations Dr. Selman for #ATS2024 Amberson Award! I wish could be there - but will cheer from New Haven!! And yes, you both deserve it our greatest honors!! Felicitaciones Moises & love to Annie!! #AnnieAndMoises #TheBest 🥰 #CurePF4All

Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis. Our latest work in press now ATS Blue Journal Great collaborative project with GRI Bio, Inc. atsjournals.org/doi/abs/10.116… #cureipf

I guess that's a sign of success - the day after I posted that the #ILDImmuneCellAtals was up - the website crushed because of heavy traffic!!! Now, just in time for Friday it's up again at ildimmunecellatlas.com enjoy!

Thanks to Tom McLellan, BA, MA, MRCP, for his contribution to the August 15 issue Deep Learning–based Segmentation of CT Scans Predicts Disease Progression and Mortality in IPF Muhunthan Thillai Phil Molyneaux Toby Maher American Thoracic Society (ATS) atsjournals.org/doi/full/10.11…

Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!! #CureIPF boehringer-ingelheim.com/us/topline-res…

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with

❗Patients with idiopathic pulmonary fibrosis (#IPF) had less #FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg #deupirfenidone (PureTech), according to phase 2b ELEVATE IPF trial results. Toby Maher Read more🔽 healio.com/news/pulmonolo…

Happy holidays everyone! We are late this year but here is the link to the 5th international symposium on ILDs in rheumatic diseases. Registration is open and free. January 17-19th 1400 CET. Click on internationalild2025.virtualevent.it World Scleroderma Foundation Toby Maher Vincent Cottin @PhilippeDieude

Lauren R. Sorce Sebastian Palmqvist Niklas Mattsson-Carlgren Jan De Waele MD Most Viewed JAMA 2024: Interstitial Lung Disease 🔗 ja.ma/49HAZ52 Toby Maher

Join us for the next episode in the specialty series on Tuesday 18 February at 6.30pm! Our panel Rachel Tattersall, Sarah Mackie and Toby Maher will discuss key updates in rheumatology. Followed by a question and answer session. Book your place now: ow.ly/cLri50UXRCi

Fibrosis: cross-organ biology and pathways to development of innovative drugs nature.com/articles/s4157… This new Review highlights core pathways active in fibrotic conditions across organs, and proposes strategies to improve the translation of potential antifibrotic drugs

Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non-Responders in IPF? onlinelibrary.wiley.com/doi/10.1111/re… and Editorial by Toby Maher @tobymmaher on recent research: onlinelibrary.wiley.com/doi/10.1111/re… Follow us on Bluesky: @respirology.bsky.social

Join Strados Labs and Toby Maher at #ATS2025 for an engaging session on the often-overlooked symptom of cough in pulmonary fibrosis and ways we can address the gap. May 19, 11:55 AM PST | Exhibitor Hall Innovation Hub #7 We look forward to seeing you there! #IPF

#ArtificialIntelligence and the Diagnosis of #InterstitialLungDisease: Are We Ready for ChatMDT?! onlinelibrary.wiley.com/doi/full/10.11… an Editorial by Toby Maher on recent research: onlinelibrary.wiley.com/doi/10.1111/re… Follow us on Bluesky: @respirology.bsky.social

A reminder to tune in to our session at #ATS2025 on cough in pulmonary fibrosis. Join Toby Maher to discuss how new technologies and patient-reported outcomes can address this gap in IPF research. Add to your calendar and join us! calendarlink.com/event/8aCAe #IPF #digitalhealth

Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf

Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team nejm.org/doi/full/10.10…

When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!! nejm.org/doi/full/10.10…

Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!